Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) is rallying 20% in pre-open action following preliminary dat from two ongoing clinical trials evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE